Core Viewpoint - NeurAxis, Inc. is set to report its financial results for the fourth quarter and fiscal year 2024 on March 20, 2025, and will hold a conference call to discuss these results [1] Group 1: Financial Reporting - The financial results will cover the period ended December 31, 2024 [1] - A conference call is scheduled for March 20, 2025, at 9:00 am ET to review the results [1][2] Group 2: Company Overview - NeurAxis, Inc. focuses on neuromodulation therapies for chronic and debilitating conditions in both children and adults [4] - The company is advancing its proprietary IB-Stim™ therapy, which is FDA cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8-21 [4] - Additional clinical trials for PENFS technology are ongoing for various pediatric and adult conditions with significant unmet healthcare needs [4]
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025